


One of the largest and most trusted custom antibody suppliers in the USA.

9 of the top 10 pharmaceutical companies' are SDIX customers.

Be a part of the success.



Genomic Antibody Technology™ packages:

- Rabbit polyclonal antibodies—AP & sera
- Mouse polyclonal antibodies
- Mouse monoclonal antibodies
- GAT hybridoma development

©2009 Pharmaceutical Executive Magazine's Industry Ranking.

SDIX: delivering application-driven immuno-solutions

SDIX is a biotechnology company, expert at creating advantage by providing quality, innovative, and effective immuno-solutions to the Pharmaceutical, Biotechnology, Diagnostics, and Food Safety markets. Our fully integrated suite of immuno-solutions includes:

- Assay design and development
- Antigen design and production
- Immunization strategy and animal management
- Hybridoma development
- Storage and scalable production
- Product formulation of critical reagents

For nearly 20 years, SDIX has created immuno-solutions that advance our customers' immuno-based work, including Genomic Antibody Technology™ (GAT) for diagnostic-grade clinical assays and research projects. From antibody candidate to critical high-quality reagent formulation, GAT enables fast, robust design and development of antibodies and antibody panels with high specificity, sensitivity, and reliability.

Highest quality standards

- AAALAC-accredited
- USDA-licensed
- Managed by current Good Manufacturing Practices
- ISO 9001:2008—certified
- Registered with the NIH Office of Laboratory Animal Welfare
- AALAS-certified animal technicians
- All animal-related procedures and protocols are reviewed and authorized by the Institutional Animal Care and Use Committee (IACUC)



Creating advantage with a fully integrated suite of immuno-solutions

Find out how our expertise and experience can drive your research forward by visiting www.sdix.com or calling 800.481.9737.



111 Pencader Drive
Newark, DE 19702 USA

P 302.456.6789
F 302.861.3730
T 800.481.9737 USA
www.sdix.com




Antibody development
has never been this powerful:
Genomic Antibody Technology™

Creating advantage with
a fully integrated suite
of immuno-solutions.



The power of Genomic Antibody Technology™ (GAT)

- Up to 50% reduction in antibody development costs
- Dramatically increase assay success rates
- No antigen to make or ship
- Agility in antigen strategy via bioinformatic analysis
- Native conformation of antigen expressed *in vivo* ensures structural fidelity



How GAT works


GAT is a new way to think about protein immunogens.

- You supply protein sequence or DNA code as electronic information
- Bioinformatic analysis of the protein antigen
- Transient transfection of animals with a plasmid encoding for the protein antigen
- Expression of the protein *in vivo*
- Recognition of the protein by the immunogen

Benefits of a large immunogen


Using an advanced bioinformatic analysis platform, a 100 amino acid region of your target protein is selected as the immunogen.

- More likely to contain surface-exposed epitopes
- More potential epitopes
- More likely to fold into native protein structure




Consistent results in complex assays

GAT antibodies are designed to recognize the target protein in the native conformation, enabling their use in diverse applications.




Model organism antibodies generated with GAT



C. elegans KNL-2 epigenetic control protein. Arshad Desai, UCSD/UNC Chapel Hill.


WT vs. KO in zebrafish embryo eye modeling Usher Syndrome. Jennifer Phillip, Ph.D, U. of Oregon/LSU HSC.

GAT mAb for use as therapeutic candidate



Cellular Growth Inhibition using anti-TNFR1 GAT mAb.

Preferential binding to native epitopes



Rabbit polyclonal antibodies were generated against human EGFR. (E) Western blot with pure full-length human EGFR from A431 cells probed with either GA3177 or GA3179. (F) Sandwich ELISA with pure full-length human EGFR from A431 cells. GA3177 is used as the capture antibody and GA3179 as the detector.

Sequence-based antibody production complements other discovery platforms

GAT complements other sequence-based technologies such as expression microarrays and RNAi knockdown models. The sequence information inherent in these technologies easily becomes GAT antigen information.



RNAi knockdown confirmation of Ambra1. Gian Maria Fimia, Cell Biology Lab, National Institute for Infectious Diseases. L. Spallanzani, IRCCS, Rome, Italy.